BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33872924)

  • 1. Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1,3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile.
    Abdel-Aziz SA; Taher ES; Lan P; Asaad GF; Gomaa HAM; El-Koussi NA; Youssif BGM
    Bioorg Chem; 2021 Jun; 111():104890. PubMed ID: 33872924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies.
    Alfayomy AM; Abdel-Aziz SA; Marzouk AA; Shaykoon MSA; Narumi A; Konno H; Abou-Seri SM; Ragab FAF
    Bioorg Chem; 2021 Mar; 108():104555. PubMed ID: 33376011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
    Somakala K; Tariq S; Amir M
    Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile.
    Abdelazeem AH; El-Saadi MT; Safi El-Din AG; Omar HA; El-Moghazy SM
    Bioorg Med Chem; 2017 Jan; 25(2):665-676. PubMed ID: 27916468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new 2-(3-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)thiazole derivatives with potential analgesic and anti-inflammatory activities: In vitro, in vivo and in silico investigations.
    Mohammed ER; Abd-El-Fatah AH; Mohamed AR; Mahrouse MA; Mohammad MA
    Bioorg Chem; 2024 Jun; 147():107372. PubMed ID: 38653152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel pyrazole based Urea/Thiourea derivatives as multiple targeting VEGFR-2, EGFR
    Fadaly WAA; Nemr MTM; Kahk NM
    Bioorg Chem; 2024 Jun; 147():107403. PubMed ID: 38691909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents.
    Ahmed EM; Kassab AE; El-Malah AA; Hassan MSA
    Eur J Med Chem; 2019 Jun; 171():25-37. PubMed ID: 30904755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel class of benzimidazole-thiazole hybrids: The privileged scaffolds of potent anti-inflammatory activity with dual inhibition of cyclooxygenase and 15-lipoxygenase enzymes.
    Maghraby MT; Abou-Ghadir OMF; Abdel-Moty SG; Ali AY; Salem OIA
    Bioorg Med Chem; 2020 Apr; 28(7):115403. PubMed ID: 32127262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugation of 4-aminosalicylate with thiazolinones afforded non-cytotoxic potent in vitro and in vivo anti-inflammatory hybrids.
    Abdu-Allah HHM; Abdelmoez AAB; Tarazi H; El-Shorbagi AA; El-Awady R
    Bioorg Chem; 2020 Jan; 94():103378. PubMed ID: 31677858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory drug approach: Synthesis and biological evaluation of novel pyrazolo[3,4-d]pyrimidine compounds.
    Atatreh N; Youssef AM; Ghattas MA; Al Sorkhy M; Alrawashdeh S; Al-Harbi KB; El-Ashmawy IM; Almundarij TI; Abdelghani AA; Abd-El-Aziz AS
    Bioorg Chem; 2019 May; 86():393-400. PubMed ID: 30763886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective cyclooxygenase inhibition and ulcerogenic liability of some newly prepared anti-inflammatory agents having thiazolo[4,5-d]pyrimidine scaffold.
    Bakr RB; Ghoneim AA; Azouz AA
    Bioorg Chem; 2019 Jul; 88():102964. PubMed ID: 31075742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel tetrazole-based selective COX-2 inhibitors: Design, synthesis, anti-inflammatory activity, evaluation of PGE
    Labib MB; Fayez AM; El-Nahass ES; Awadallah M; Halim PA
    Bioorg Chem; 2020 Nov; 104():104308. PubMed ID: 33011534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pyridazine derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents; design, synthesis and biological evaluation.
    Ahmed EM; Hassan MSA; El-Malah AA; Kassab AE
    Bioorg Chem; 2020 Jan; 95():103497. PubMed ID: 31838289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of new hexahydropyrimido[1,2-
    Hassanein HH; Abdel Rahman DE; Fouad MA; Ahmed RF
    Future Med Chem; 2021 Apr; 13(7):625-641. PubMed ID: 33624540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-1/COX-2 inhibition assays and histopathological study of the new designed anti-inflammatory agent with a pyrazolopyrimidine core.
    Abdelall EKA; Lamie PF; Ahmed AKM; El-Nahass ES
    Bioorg Chem; 2019 May; 86():235-253. PubMed ID: 30716621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
    AboulWafa OM; Daabees HMG; Badawi WA
    Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and development of thiazole leads as COX-2/5-LOX inhibitors through in-vitro and in-vivo biological evaluation for anti-inflammatory activity.
    Jacob P J; Manju SL
    Bioorg Chem; 2020 Jul; 100():103882. PubMed ID: 32361295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR inhibitors from cancer to inflammation: Discovery of 4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide as a novel anti-inflammatory EGFR inhibitor.
    Elkamhawy A; Hassan AHE; Paik S; Sup Lee Y; Lee HH; Shin JS; Lee KT; Roh EJ
    Bioorg Chem; 2019 May; 86():112-118. PubMed ID: 30685642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.